← Back to Clinical Trials
Recruiting Phase 2 NCT07420530

NCT07420530 Respiratory and Real-time Dynamics in Exercise-Induced Paradoxical Vocal Fold Motion

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07420530
Status Recruiting
Phase Phase 2
Sponsor Indiana University
Condition Exercise-Induced Vocal Cord Dysfunction
Study Type INTERVENTIONAL
Enrollment 130 participants
Start Date 2026-08-12
Primary Completion 2032-01-20

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 26 Years
Study Type INTERVENTIONAL
Interventions
Carbon DioxideMechano-acoustic device

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.

This trial targets 130 participants in total. It began in 2026-08-12 with a primary completion date of 2032-01-20.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The overall objectives of the proposed research are to: 1. Evaluate the diagnostic validity of a novel mechano-acoustic signatures of task-characteristic activity during symptomatic and asymptomatic breathing in Exercise-Induced Laryngeal Obstruction (EILO) patients with the use of a novel miniature, soft wearable skin-mounted device, 2. Identify the mechanism/s of paradoxical respiratory control in EILO by quantifying the relationship between pulmonary mechanics, partial pressure of carbon dioxide (PCO2) maintenance, and vocal fold aperture prior to and during symptomatic and asymptomatic exercise ventilation, and 3. Identify unique biophysiological factors contributing to EILO among exercisers with and without EILO. Findings will be highly novel and clinically significant for early identification and management of EILO. The main study will enroll 60 participants with EILO and 60 without EILO to complete three separate visits: 1. Exercise treadmill study 2. Free running with the device on the neck 3. Undergoing MRI (Magnetic Resonance Imaging) of the vocal tract. An additional substudy limited to the mechanoacoustic device will enroll 10 additional participants (5 healthy and 5 with EILO). These participants will complete a single study visit during which the mechano-acoustic device will be worn during four sequential conditions.

Eligibility Criteria

Inclusion Criteria for Exercise-Induced Laryngeal Obstruction (EILO): * Physically active \>2.5 hours per week * Patients with EILO, as diagnosed by routine clinical examination by physician and/or speech language pathologist * Age range of 18-26 years * Greater difficulty breathing inside compared to out and difficulty breathing which is exacerbated at peak exercise and stops 1-5 minutes after exercise * Score of 7 or higher on the Dyspnea Index, which is a validated instrument to capture participant self-report of upper airway dyspnea symptoms. * Classified as low risk, based on the modified Physical Activity Readiness Questionnaire (PAR-Q) questionnaire, body mass index, and non-smoking status * Negative history of voice disorders, self-report of cognitive difficulties, asthma or other lung disease, cardiac disease, serious orthopedic injuries, current uncontrolled hypertension, illicit drug use, seizure/epilepsy, claustrophobia, use of beta blockers. * No metallic, mechanical or magnetic implants such as cardiac devices, cochlear, or other non-removable ear implants, any prosthesis, stents, deep brain stimulator, etc. Inclusion Criteria for Controls * Physically active \>2.5 hours per week * Age range of 18-26 years * Classified as low risk, based on the modified PAR-Q questionnaire, body mass index, and non-smoking status * Negative history of voice disorders, self-report of cognitive difficulties, asthma or other lung disease, cardiac disease, serious orthopedic injuries, current uncontrolled hypertension, illicit drug use, seizure/epilepsy, claustrophobia, use of beta blockers. * No metallic, mechanical or magnetic implants such as cardiac devices, cochlear, or other non-removable ear implants, any prosthesis, stents, deep brain stimulator, etc. Exclusion Criteria for EILO: * Individuals older than 26 years and younger than 18 years of age. * Women who are pregnant or could possibly be pregnant. * BMI \> 25 kg/m2 * A 'yes' answer to any of the 14 questions on the PAR-Q pre-participation questionnaire * Current smoker * Positive history of voice disorders, self-report of cognitive difficulties, asthma or other lung disease, cardiac disease, serious orthopedic injuries, current uncontrolled hypertension, illicit drug use, seizure/epilepsy, claustrophobia, use of beta blockers. * Presence of metallic, mechanical or magnetic implants such as cardiac devices, cochlear, or other non-removable ear implants, any prosthesis, stents, deep brain stimulator, etc. * Do not report the following: Greater difficulty breathing inside compared to out and difficulty breathing which is exacerbated at peak exercise and stops 1-5 minutes after exercise Exclusion Criteria for Controls * Individuals older than 26 years and younger than 18 years of age. * Women who are pregnant or could possibly be pregnant. * BMI \> 25 kg/m2 * A 'yes' answer to any of the 14 questions on the PAR-Q pre-participation questionnaire * Current smoker * Positive history of voice disorders, self-report of cognitive difficulties, asthma or other lung disease, cardiac disease, serious orthopedic injuries, current uncontrolled hypertension, illicit drug use, seizure/epilepsy, claustrophobia, use of beta blockers. * Presence of metallic, mechanical or magnetic implants such as cardiac devices, cochlear, or other non-removable ear implants, any prosthesis, stents, deep brain stimulator, etc. * Significant acute or chronic medical, neurologic, or illness in the patient that, in the judgment of the Principal Investigator, could compromise subject safety, limit the ability to complete the study, and/or compromise the objectives of the study

Contact & Investigator

Central Contact

Rita R Patel

✉ patelrir@iu.edu

📞 812-855-3886

Principal Investigator

Rita Patel

PRINCIPAL INVESTIGATOR

Indiana University

Frequently Asked Questions

Who can join the NCT07420530 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 26 Years, studying Exercise-Induced Vocal Cord Dysfunction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT07420530 trial and what does that mean for participants?

Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.

Is NCT07420530 currently recruiting?

Yes, NCT07420530 is actively recruiting participants. Contact the research team at patelrir@iu.edu for enrollment information.

Where is the NCT07420530 trial being conducted?

This trial is being conducted at Bloomington, United States.

Who is sponsoring the NCT07420530 clinical trial?

NCT07420530 is sponsored by Indiana University. The principal investigator is Rita Patel at Indiana University. The trial plans to enroll 130 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology